MiNK Therapeutics, Inc. (NASDAQ:INKT) saw its stock soar by 200% following the announcement of a remarkable cancer remission case linked to its investigational cell therapy, agenT-797.
The clinical-stage biotech firm revealed that a patient with advanced, treatment-resistant testicular cancer achieved full remission after receiving a single infusion of its allogeneic invariant natural killer T (iNKT) cell therapy in combination with nivolumab. The breakthrough was highlighted in a recent publication in Nature’s Oncogene.
The patient, who had previously failed numerous therapies—including platinum-based chemotherapy, stem cell transplant, and various immune checkpoint inhibitors—has remained disease-free for over two years. The treatment showed a strong safety profile with no signs of graft-versus-host disease or cytokine release syndrome, and donor iNKT cells remained detectable for up to six months post-infusion.
This case adds to growing optimism around agenT-797’s potential in treating solid tumors. At the AACR’s 2025 Immuno-Oncology conference, MiNK also shared encouraging data from its Phase 2 gastric cancer trial, where several patients showed immune responses and survival exceeding 12 months despite resistance to prior therapies.
MiNK Therapeutics is developing agenT-797 as an off-the-shelf, cryopreserved iNKT cell therapy to treat cancers, immune disorders, and inflammatory diseases. The firm is actively enrolling for its ongoing Phase 2 trial in gastric cancer, with additional data expected later this year.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.